Nobilon International BV, part of Organon, was founded in 2003. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines.
Nobilon draws on expertise from its related businesses Organon, Intervet and Diosynth.
Organon is a leading international player in several key areas of human pharmaceuticals, in particular prescription medicines.
Intervet is one of the world’s largest animal healthcare companies, supplying customers with animal healthcare products, including vaccines and pharmaceuticals.
Diosynth plays a prominent global role in the production of complex active (bio)pharmaceutical ingredients.
Through the establishment of Nobilon International, it is aimed to harvest some of the synergies that exist between these businesses and to diversify further into biotechnology. Organon has valuable knowledge in drug development in the field of immunology and biotechnology of human therapeutics. Diosynth will contribute through its experience in process development and production of recombinant proteins, synthetic peptides and monoclonal antibodies. Intervet, with a leadership position in animal vaccines, will bring its research know-how and technological expertise in vaccines to the venture.
Nobilon intends to become a fully integrated biotechnology company encompassing research, development, registration, production and commercialization of selected vaccines.